425: Cross Country Healthcare Merger Update and Shareholder Lawsuits

Cross Country Healthcare provides supplemental disclosures regarding its merger and addresses ongoing litigation from shareholders questioning proxy statement completeness.

Summary

• Cross Country Healthcare, Inc. (the Company) has filed supplemental disclosures related to its proposed merger with KL Criss Cross Intermediate, LLC and its subsidiary, KL Criss Cross Merger Sub, Inc.
• A special meeting for stockholders to approve the merger is scheduled for July 16, 2026, with the Company expecting to complete the merger in the third quarter of 2026, subject to shareholder approval and other closing conditions.
• The Company has received demand letters from shareholders alleging deficiencies in the proxy statement disclosures and has been named in two lawsuits (Malone v. Cross Country Healthcare, Inc. and Walsh v. Cross Country Healthcare, Inc.) filed in New York Supreme Court.
• These lawsuits allege material incompleteness in the proxy statement due to misrepresentations and omissions, seeking to enjoin the consummation of the merger.
• The Company believes the claims in the demand letters and lawsuits are without merit but is voluntarily supplementing its disclosures to mitigate costs and risks associated with the litigation.
• Supplemental disclosures clarify interests of directors and executive officers in the merger, including potential consulting agreements for executives and board service for a director.
• Financial analyses performed by BofA Securities, including selected public companies and precedent transactions, are updated, with enterprise value to EBITDA multiples for selected transactions ranging from 8.9x to 11.5x.
• A discounted cash flow analysis was performed, using a perpetuity growth rate range of 3.0% to 4.0% and discount rates of 9.0% to 11.0%.
• Analyst price targets for Cross Country common stock, when discounted, indicated a range of $9.09 to $13.64 per share.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily provides procedural updates and supplemental information regarding a merger, while also disclosing ongoing litigation which introduces some uncertainty.

Positives

• The Company is proactively addressing shareholder concerns by providing supplemental disclosures to the proxy statement.
• The merger is expected to be completed in the third quarter of 2026, indicating progress towards the transaction.
• BofA Securities' financial analyses provide a valuation framework for the merger, with a range of implied equity values per share.
• The Company's management believes the claims in the lawsuits are without merit, suggesting confidence in the merger process and disclosures.

Negatives

• Two lawsuits have been filed by purported stockholders alleging material incompleteness in the proxy statement due to misrepresentations and omissions.
• Shareholder demand letters allege deficiencies in proxy statement disclosures, threatening further litigation.
• The ongoing litigation and potential for additional lawsuits introduce costs, risks, and uncertainties.
• The Company's management time may be diverted to address transaction-related issues and ongoing litigation.

Risks

• The risk that a condition of closing the merger may not be satisfied or that the closing might otherwise not occur.
• The risk that required regulatory approvals may not be obtained or may be subject to unanticipated conditions.
• Diversion of management time on transaction-related issues and ongoing business operations.
• Adverse effects on the market price of Company Common Shares due to the merger announcement.
• Adverse effects on the Company's ability to retain customers, key personnel, and maintain relationships with suppliers and customers.
• The occurrence of any event, change, or circumstance that could give rise to the termination of the Merger Agreement.
• The risk that competing offers will be made.
• Unexpected costs, charges, or expenses resulting from the merger.
• Potential litigation relating to the merger that could be instituted against the parties or their respective directors, managers, or officers.
• Worldwide economic or political changes affecting the markets the Company's businesses serve.
• Effects from global pandemics, epidemics, or other public health crises.
• Changes in marketplace conditions, such as alternative modes of healthcare delivery, reimbursement, and customer needs.
• Disruptions in the global credit and financial markets, including diminished liquidity and credit availability.
• Changes in international trade agreements, including tariffs and trade restrictions.
• Cyber-security vulnerabilities.
• Foreign currency volatility.
• Swings in consumer confidence and spending.
• Costs of providing services.
• Retention of key employees.
• Outcomes of legal proceedings, claims, and investigations.

Future Outlook

The Company expects to complete the merger in the third quarter of 2026, subject to the satisfaction of closing conditions, including stockholder approval. Forward-looking statements indicate potential risks and uncertainties related to the timing and consummation of the merger, regulatory approvals, business disruption, and financial market conditions.

Management Comments

• The Company believes that the claims asserted in the Lawsuits and the Demand Letters are without merit.
• The Company specifically denies all allegations set forth in the Malone Action and the Walsh Action, as well as the Demand Letters, and denies that any additional disclosure in the Proxy Statement was or is required.
• As of the date of this proxy statement, Cross Country's executive officers have not entered into any new individualized compensation arrangements.
• There was no discussion of post-closing employment or retention prior to signing, but on May 14, 2026, Knox Lane initiated conversations with Mr. Burns and Ms. Ball with respect to a possible consulting agreement for transition and advisory services with Parent or one of its subsidiaries upon closing.
• Knox Lane has also had discussions with Mr. Clark regarding serving on the board of one of its subsidiaries.

Industry Context

StockSavvy.ai notes that the supplemental disclosures and litigation surrounding the Cross Country Healthcare merger are common in the healthcare staffing industry, particularly when significant transactions are involved. The financial analyses presented by BofA Securities, including comparisons to precedent transactions and public companies, are standard practice for evaluating such deals within the sector.

Comparison to Industry Standards

• Selected precedent transactions in the healthcare staffing industry announced since 2010 showed enterprise value to LTM EBITDA multiples ranging from 8.9x to 11.5x, with a mean of 10.7x and a median of 11.0x.
• The financial analysis by BofA Securities applied an enterprise value to EBITDA multiple reference range of 4.8x to 7.5x to Cross Country's estimated adjusted EBITDA for 2026, which appears to be a forward-looking multiple, distinct from the historical LTM multiples of precedent transactions.
• The discounted cash flow analysis used a perpetuity growth rate range of 3.0% to 4.0% and discount rates of 9.0% to 11.0%, which are typical for valuation analyses in the healthcare services sector.

Management Changes

Legal Proceedings

• Two lawsuits (Malone v. Cross Country Healthcare, Inc. and Walsh v. Cross Country Healthcare, Inc.) have been filed alleging material incompleteness in the proxy statement due to misrepresentations and omissions.
• Demand letters have been received from purported stockholders alleging deficiencies in the proxy statement disclosures.

Related Party Transactions

• Potential consulting agreements for Mr. Burns and Ms. Ball with Parent or its subsidiaries post-merger.
• Potential board service for Mr. Clark on one of Parent's subsidiaries post-merger.

Stakeholder Impact

• Shareholders: Voting on the merger, potential impact on share price due to litigation and merger announcement, potential for future compensation arrangements for executives.
• Employees: Potential impact on retention of key personnel due to merger announcement and ongoing litigation.
• Management: Diversion of time due to transaction-related issues and litigation, potential for new employment or consulting roles post-merger.

Next Steps

• Stockholders to vote on the merger at the Special Meeting scheduled for July 16, 2026.
• Completion of the merger is expected in the third quarter of 2026, subject to satisfaction of closing conditions.
• Potential for additional lawsuits or demand letters related to the merger.
• Potential for new employment or consulting arrangements for executives post-merger.

Key Dates

Recommendation

The filing primarily concerns updates to merger disclosures and ongoing litigation. While the merger is progressing, the shareholder lawsuits introduce uncertainty and potential delays or complications. The financial analyses provide context but do not offer a clear indication of superior or inferior performance relative to expectations. Therefore, a 'hold' recommendation is appropriate pending further clarity on the litigation and the definitive outcome of the merger.

Keywords

Cross Country Healthcare, Merger Agreement, Form 8-K, Proxy Statement, Special Meeting, Stockholder Litigation, BofA Securities, Financial Analysis, EBITDA, Enterprise Value, Discounted Cash Flow, Corporate Governance, SEC Filing